Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
Company Overview
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company focused on harnessing targeted protein degradation to pioneer a new generation of medicines. Leveraging advanced drug discovery techniques, C4 Therapeutics seeks to address diseases that are resistant to conventional treatments by eliminating harmful proteins through the body’s natural ubiquitin-proteasome system. The company is recognized for its scientific ingenuity and its commitment to transforming patient care across difficult-to-treat oncology indications.
Innovative Technology and Platforms
The company’s core approach centers on selective and rapid protein degradation using proprietary platforms. The TORPEDO® platform enables the efficient design and optimization of small-molecule medicines. This platform, along with their advanced degrader technologies, facilitates precise targeting of pathogenic proteins and offers a novel mechanism of action that distinguishes their molecules from traditional inhibitors. By employing these cutting-edge tools, C4 Therapeutics is positioned to overcome challenges such as drug resistance and the targeting of previously "undruggable" proteins.
Clinical Pipeline
C4 Therapeutics has built a robust pipeline of oral degrader candidates that are advancing through clinical trials. Notable assets include:
- Cemsidomide: An oral degrader targeting IKZF1/3 designed for potential application in hematologic malignancies such as multiple myeloma and non-Hodgkin’s lymphoma. Its innovative mechanism aims to improve patient outcomes by addressing key oncogenic transcription factors.
- CFT1946: An orally bioavailable degrader targeting BRAF V600X mutant proteins, developed for solid tumors. This candidate is engineered to overcome common resistance mechanisms and has demonstrated promising preclinical and early clinical data.
- CFT8919: Focused on targeting EGFR mutations, particularly the oncogenic L858R variant, this candidate is being developed to address non-small cell lung cancer. It exemplifies the company’s commitment to expanding its impact in both regional and global markets through strategic partnerships.
Collaborations and Strategic Partnerships
C4 Therapeutics enhances its technological and clinical capabilities through strategic collaborations with prominent industry players. Its partnerships with Biogen, Merck, MKDG, and Betta Pharmaceuticals underpin its expertise in drug discovery and clinical development. These alliances not only bolster the company’s scientific credibility but also provide additional validation of its targeted protein degradation approach.
Market Position and Value Proposition
In the competitive landscape of biopharmaceutical innovation, C4 Therapeutics distinguishes itself with a focused strategy on targeted protein degradation. The company offers a differentiated value proposition by aiming to rapidly eliminate disease-driving proteins, thereby potentially overcoming the limitations of standard small-molecule inhibitors. This approach underlines its commitment to developing therapies for patient populations with high unmet medical needs.
Scientific Rigor and Industry Expertise
Emphasizing transparency and scholarly integrity, C4 Therapeutics integrates rigorous scientific research with comprehensive clinical validation. Its communication strategy, supported by detailed clinical studies and data presentations at major scientific venues, reflects its deep expertise and reinforces the trustworthiness of its research methodologies.
Conclusion
C4 Therapeutics stands as a prime example of innovation in the realm of targeted protein degradation, bridging cutting-edge science with clinical application. For investors and industry analysts, the company’s strategic focus on developing orally bioavailable small-molecule degraders offers a unique insight into the evolving therapeutic landscape aimed at overcoming challenging diseases through novel mechanisms of action.
C4 Therapeutics (CCCC) reported its Q4 and full year 2024 financial results, highlighting progress in its degrader portfolio. The company ended 2024 with $267.3 million in cash, providing runway into 2027.
Key clinical developments include cemsidomide showing a 36% overall response rate in Multiple Myeloma and 38% across NHL subtypes. In PTCL, cemsidomide achieved a 44% overall response rate. Clinical trials for both indications are expected to initiate in early 2026.
Financial highlights for 2024 include revenue of $35.6 million, up from $20.8 million in 2023. R&D expenses decreased to $110.6 million from $117.7 million, while G&A expenses remained flat at $42.1 million. Net loss improved to $105.3 million ($1.52 per share) compared to $132.5 million ($2.67 per share) in 2023.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in two major investor conferences in March 2025.
The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3rd at 9:10 am ET in Boston, MA. A live webcast will be accessible through the company's website's Events & Presentations page, with replay available for approximately 30 days after the event.
Additionally, management will attend the Leerink Partners Global Healthcare Conference on March 9th in Miami, FL.
C4 Therapeutics (CCCC) announced its 2025 milestones for its clinical portfolio of degrader medicines in oncology. The company highlighted progress across three main programs: cemsidomide for multiple myeloma and non-Hodgkin's lymphoma, CFT1946 for BRAF V600X solid tumors, and CFT8919 for non-small cell lung cancer.
Key developments include cemsidomide's promising data presented at ASH, showing a 36% overall response rate in multiple myeloma and 38% in non-Hodgkin's lymphoma. CFT1946's Phase 1 monotherapy dose escalation is expected to complete in H1 2025, with data in melanoma and colorectal cancer expected in H2 2025. The company's cash runway is expected to fund operations into 2027.
The company plans to initiate new clinical studies for cemsidomide in early 2026, including combinations with other agents for multiple myeloma and monotherapy for peripheral T-cell lymphoma. Data from CFT8919's Phase 1 study in Greater China will inform future development plans.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Andrew Hirsch, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM PST (5:15 PM EST).
The presentation will be accessible via live webcast through C4T's website in the Events & Presentations section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the presentation.
C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical benefit rate at the highest dose level. The drug demonstrated a well-tolerated safety profile with manageable neutropenia.
In NHL, cemsidomide monotherapy showed a 38% overall response rate and 19% complete metabolic response rate. Notably, in peripheral T-cell lymphoma, the drug achieved a 44% overall response rate and 25% complete metabolic response rate. The company is positioning cemsidomide for future development in multiple myeloma combination regimens and various NHL subtypes.
C4 Therapeutics (Nasdaq: CCCC) has appointed Steve Hoerter to its Board of Directors. Hoerter brings over 30 years of oncology commercialization and leadership experience, most recently serving as president and CEO of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. At Deciphera, he led the successful approval and launch of QINLOCK® for gastrointestinal stromal tumors. His previous roles include chief commercial officer at Agios Pharmaceuticals, where he oversaw the launches of TIBSOVO® and IDHIFA® for acute myeloid leukemia.
C4 Therapeutics (Nasdaq: CCCC) announced that its partner Betta Pharmaceuticals has dosed the first patient in a Phase 1 clinical trial of CFT8919 in Greater China. CFT8919 is an orally bioavailable allosteric degrader targeting EGFR L858R mutations in non-small cell lung cancer (NSCLC). The drug aims to overcome limitations of current EGFR tyrosine kinase inhibitors, particularly for patients with the L858R mutation. In China, where approximately 693,000 NSCLC cases are diagnosed annually, about 50% have EGFR mutations, with L858R being present in roughly 40% of EGFR-mutated cases. The collaboration with Betta Pharmaceuticals could yield up to $357 million in milestones plus royalties for C4T.
C4 Therapeutics (Nasdaq: CCCC) announced the acceptance of two abstracts from their ongoing Phase 1/2 trial of cemsidomide for presentation at the ASH Annual Meeting in December 2024. The presentations will include Non-Hodgkin's lymphoma (NHL) data as an oral presentation and multiple myeloma (MM) data as a poster presentation. Both presentations will feature updated data compared to the abstracts on December 8th. The company will host an investor webcast at 2 PM PT following the presentations to discuss the results.
Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.
C4 Therapeutics (CCCC) reported Q3 2024 financial results with revenue of $15.4 million, up from $11.1 million in Q3 2023. Net loss was $24.7 million ($0.35 per share). The company ended Q3 with $284.4 million in cash and equivalents, expected to fund operations into 2027.
Key highlights include progress in clinical trials for cemsidomide in multiple myeloma and non-Hodgkin's lymphoma, with data to be presented at ASH. CFT1946 showed promising initial monotherapy data with a well-tolerated safety profile. The company earned an $8 million milestone payment from Biogen for delivering a second development candidate.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
What is the primary focus of C4 Therapeutics?
How does C4 Therapeutics' technology work?
What are the key assets in C4 Therapeutics' pipeline?
How do collaborations enhance the company’s capabilities?
What competitive advantage does C4 Therapeutics offer?
How does C4 Therapeutics ensure scientific credibility?
